Innate lymphoid cells are a family of tissue-resident immune cells that shape the first-line defenses at mucosal surfaces. Unlike adaptive T and B cells, they lack antigen-specific receptors but release large amounts of cytokines that regulate the epithelial barrier, microbial communities, and downstream adaptive responses. Their rapid, local actions make them central to homeostasis and to early responses against pathogens.
Subsets and effector roles
Three major groups mirror classical T helper programs. ILC1 produce interferon gamma and contribute to control of intracellular pathogens and maintenance of epithelial integrity in the gut and lung. ILC2 secrete interleukin 5 and interleukin 13, driving mucus production, epithelial repair, and type 2 inflammation relevant to helminth defense and allergic disease. ILC3 produce interleukin 17 and interleukin 22, promoting antimicrobial peptide expression and controlling extracellular bacteria at intestinal and oral mucosa. Andrew McKenzie MRC Laboratory of Molecular Biology described the defining features of ILC2 and their role in tissue repair. Marco Colonna Washington University School of Medicine has characterized ILC3 functions in mucosal barrier maintenance and interactions with commensal microbes. David Artis University of Pennsylvania has shown how ILC-driven cytokines orchestrate epithelial and myeloid responses during infection.
Activation, tissue residency, and cross-talk
Mucosal epithelial cells sense damage or microbes and release alarmins such as interleukin 25 interleukin 33 and thymic stromal lymphopoietin that rapidly activate ILCs. Once activated, ILCs modulate epithelial proliferation mucus secretion and tight junctions, thereby influencing permeability and pathogen access. ILCs also interact with dendritic cells and adaptive lymphocytes, shaping antigen presentation and the balance between tolerance and inflammation. Eric Vivier Aix-Marseille University has reviewed the importance of tissue-specific niches that sustain ILC identity and function, highlighting that microenvironmental signals determine whether ILCs promote repair or drive pathology. These interactions are context-dependent and vary with age nutritional status and microbial exposure.
Clinical relevance and environmental nuance
When balanced, ILC activity preserves barrier integrity and supports symbiosis with commensal microbes. Dysregulated ILC responses contribute to disease. Excessive ILC2 activity underlies asthma and airway hyperresponsiveness while altered ILC3 function associates with inflammatory bowel disease and impaired control of intestinal bacteria. James P. Di Santo Institut Pasteur and colleagues have linked aberrant ILC activation to chronic inflammation and tissue remodeling. Environmental and cultural factors modulate these risks. In regions with high helminth burden ILC2-driven type 2 programs are prominent and can protect against severe helminth pathology while simultaneously influencing susceptibility to allergic disorders. Westernized diets and antibiotic exposure reshape the microbiota and can shift ILC3-mediated defenses, potentially increasing vulnerability to inflammatory and metabolic diseases.
Therapeutically, targeting upstream alarmins or downstream ILC cytokines offers options to restore balance while preserving protective functions. Ongoing clinical research aims to separate beneficial repair and antimicrobial roles from the inflammatory ones that cause chronic disease. Understanding how local signals tune ILC behavior at specific mucosal sites is essential for interventions that maintain barrier health without compromising host defense.